# RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes

> **NCT00379769** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 4447 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Rosiglitazone
- **DRUG:** Sulfonylurea
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00379769
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 4447 (ACTUAL)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00379769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00379769, "RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00379769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*